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Cell adhesion can be divided into cell-cell adhesion medi-
ated by three major structures, tight junctions, adherens
junctions, desmosomes, and cell-matrix adhesion, which
is for the most part integrin-based. Cell-cell interactions
play an important role in the maintenance and integrity
of tissues and organs but similar to cell-matrix complexes
may also transduce cell signaling. While this is the basics for
understanding cell adhesion and its function, the role of cell
adhesion proteins in disease, especially tumorigenesis, is far
more diverse. A summary is given in the paper presented
by Dr. Andl in this issue where she also focuses on recently
discovered cell adhesion components and the regulation of
cell adhesion molecules by miRNAs. In cancer, cell adhesion
molecules are generally thought to be deactivated in order
to aid in cancer cell dissemination and dispersal. However,
aside from the loss of function, various gain-of-function
events occur during induction and progression of cancer
that can be mediated by cell adhesion molecules. Many
of the molecules involved in these processes, such as the
components of desmosomes, were initially identiﬁed as
targets of autoimmune diseases. This special issue outlines
the latest ﬁndings in research and review articles.
Tight junctions mediate apical cell-cell adhesion and
regulate epithelial cell polarity. Members of the claudin
family are involved in a number of diseases including cancer;
however, little is known regarding the mechanisms behind
their pathophysiological function. Drs. Singh, Sharma, and
Dhawan give an overview of the current state of knowledge
in this issue. To identify cell transformation mechanisms
other than previously described, Lynch et al. investigated
the eﬀect of MMP-7 mediated cleavage of E-cadherin.
They demonstrate that loss of cell-cell adhesion is induced
following E-cadherin processing, which results in increased
cell migration, loss of polarization, and activation of RhoA.
Interactions of cell adhesion molecules with their envi-
ronment are central to their regulation and to cell migration
and invasion. In the tumor context, the array of integrin
receptors expressed causes the cells to diﬀerentially respond
to external signals, resist the eﬀects of cytotoxic drugs, and
facilitate growth and invasion through a range of diﬀerent
tissue environments encountered by invasive cancer cells.
In particular, the regulation of integrin receptor interaction
withtheextracellularmatrixisthoughttobecriticalforthose
cancers that invade and metastasize using a mesenchymal
mode of migration. Jossen et al. show a novel prostate
cancer bone metastatic model to assay drug sensitivity in
three-dimensional cultures that mimic the preclinical or
clinical setting more accurately. In here, they show that
prostate cells revert to more epithelial cells, mesenchymal-
epithelial transition (MET) in the presence of bone stroma2 Journal of Oncology
modeling later stages of metastatic colonization, and are
sensitized to radiation treatment when blocking E-cadherin
or α-integrin. Mesenchymal migration as a therapeutic
target for glioblastoma is discussed by Zhong et al. Another
potential therapeutic agent, a Src inhibitor, is described by
Yaseem et al. Comparison of SKI-606 and Iressa eﬀects,
Src/Abl and EGFR inhibitors, respectively, on cervical cancer
cell lines shows inhibition of cell proliferation. Additionally,
SKI-606 decreases cell migration and invasion through MET
accompanied by the re-expression of E-cadherin and the
recruitment of β-catenin to the cell membrane. Hironobu
Yamashita et al. demonstrate that lysophosphatidic acid,
a phospholipid growth factor, induces the stimulation of
lamellipodiaformationandenhancedcellmigrationthrough
the upregulation of the TGFβ1 target gene Laminin-322.
The role of focal adhesion kinase (FAK) phosphorylation
in the dynamic regulation of integrin-based adhesions and
cellular migration is shown in a paper by Hamadi et al.
Upon pervanadate-induced phosphorylation, FAK delocal-
izes from focal adhesions to newly formed membrane ruﬄes
in a src-dependent event. Finally, advances in nanotech-
nology that allow the study of cellular transformation in
engineered cellular environments are introduced by Siti
Hawa Ngalmi et al. Such cross-disciplinary approaches have
begun to advance our knowledge of how adhesion signaling
is organized and how cells relay information regarding
the composition and structure of the external environment
into biological activity. In particular, these advances are
being driven by novel microscopy technologies and the
continuing development of new techniques that allow us
to visualize the intricate workings of adhesion-dependent
signaling processes.
This synopsis gives a glimpse at the current leading
edge science published in this special issue of the Journal
of Oncology. We hope that these papers inspire interest in
multidisciplinary approaches as well as in the identiﬁcation
of novel therapeutics.
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